Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2025 ▲▼ | Q4 2025 ▲▼ | Change ▲▼ | Q3 2025 ▲▼ | Q4 2025 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| SPDR Gold SharesGOLD SHS(GLD) | 7,286 | 6,964 | -322 | $2.59M | $2.76M | 64.50% | +$170.0K |
| Berkshire Hathaway Inc DelCL B | 651 | 710 | +59 | $327.5K | $356.8K | 8.34% | +$29.3K |
| Spyre Therapeutics, Inc.(SYRE) | 0 | 8,919 | +8,919 | $0 | $292.2K | 6.83% | +$292.2K |
| Mind Medicine Mindmed Inc | 27,011 | 15,688 | -11,323 | $318.5K | $210.1K | 4.91% | -$108.4K |
| Kyverna Therapeutics, Inc.(KYTX) | 22,981 | 18,773 | -4,208 | $137.9K | $176.5K | 4.12% | +$38.6K |
| Compass Therapeutics, Inc.(CMPX) | 53,503 | 29,495 | -24,008 | $187.3K | $158.4K | 3.70% | -$28.9K |
| Lexeo Therapeutics, Inc.(LXEO) | 17,332 | 13,943 | -3,389 | $115.1K | $138.5K | 3.24% | +$23.4K |
| X4 Pharmaceuticals, Inc.(XFOR) | 0 | 15,557 | +15,557 | $0 | $62.2K | 1.45% | +$62.2K |
| Inhibikase Therapeutics, Inc.(IKT) | 16,393 | 28,453 | +12,060 | $26.6K | $58.3K | 1.36% | +$31.8K |
| SAB Biotherapeutics, Inc.(SABS) | 10,935 | 10,527 | -408 | $22.0K | $39.4K | 0.92% | +$17.4K |
| Context Therapeutics Inc.(CNTX) | 18,403 | 18,403 | 0 | $17.8K | $27.1K | 0.63% | +$9.2K |
| Bicara Therapeutics Inc | 10,941 | 0 | -10,941 | $172.8K | $0 | — | -$172.8K |
| Enliven Therapeutics Inc | 13,097 | 0 | -13,097 | $268.1K | $0 | — | -$268.1K |
| Rezolute, Inc.(RZLT) | 1,986,818 | 0 | -1,986,818 | $18.68M | $0 | — | -$18.68M |